🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Jeremy Grantham’s ALT Holdings & Trades

First Buy
Q4 2025
Duration Held
2 Quarters
Largest Add
Q4 2025
+172,559 Shares
Current Position
126,389 Shares
$389,278 Value

Jeremy Grantham's ALT Position Overview

Jeremy Grantham (via Grantham, Mayo, Van Otterloo & Co. LLC) currently holds 126,389 shares of Altimmune, Inc. (ALT) worth $389,278, representing 0.00% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 2 quarters.

Based on recent 13F filings, Jeremy Grantham has initiated a new position in ALT, representing a fresh investment thesis on this company. Largest reduction occurred in Q1 2026, reducing 46,170 shares.

Analysis based on 13F filings available since 2013 Q2

Jeremy Grantham's Altimmune (ALT) Holding Value Over Time

Track share changes against reported price movement

Quarterly Altimmune (ALT) Trades by Jeremy Grantham

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q1 2026 -46,170 Reduce 26.76% 126,389 $3.08
Q4 2025 +172,559 New Buy 172,559 $3.61

Jeremy Grantham's Altimmune Investment FAQs

Jeremy Grantham first purchased Altimmune, Inc. (ALT) in Q4 2025, acquiring 172,559 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Jeremy Grantham has held Altimmune, Inc. (ALT) for 2 quarters since Q4 2025.

Jeremy Grantham's largest addition to Altimmune, Inc. (ALT) was in Q4 2025, adding 172,559 shares worth $622,938.

According to the latest 13F filing for Q1 2026, Jeremy Grantham's firm, Grantham, Mayo, Van Otterloo & Co. LLC, owns 126,389 shares of Altimmune, Inc. (ALT), valued at approximately $389,278.

As of the Q1 2026 filing, Altimmune, Inc. (ALT) represents approximately 0.00% of Jeremy Grantham's publicly disclosed stock portfolio, making it one of their key holdings.

Jeremy Grantham's peak holding in Altimmune, Inc. (ALT) was 172,559 shares, as reported at the end of Q4 2025.